The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.

Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.